All Studies/Projects

RADx Tech COVID-19 Test US Study

Post Date: 
2020-08-05
   |   
Countries: 
Rationale: Scalable, inexpensive point-of-care (PoC) technologies that enable detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus are desperately needed. However, understanding the accuracy and usability of novel PoC technologies for SARS-CoV-2 is critical. Each PoC...

RADx Tech COVID-19 Test Us Bank

Post Date: 
2020-08-05
   |   
Countries: 
This study is collecting and storing lab samples of COVID-19 diagnostic tests among both people who have tested positive for COVID and those who haven’t to evaluate new COVID test and study how COVID-19 and related viruses cause disease in people.

RADx Tech COVID-19 Test Us Study

Post Date: 
2020-07-27
   |   
Countries: 
Scalable, inexpensive novel technologies that enable detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus are desperately needed. However, understanding the accuracy and usability of novel technologies for SARS-CoV-2 is critical. Each novel test needs to be evaluated...

Epidemiology and Clinical Outcomes of COVID-19 in India (ECO-19)

Post Date: 
2020-07-09
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated May 25, 2021 This is a prospective cohort study of adults with suspected COVID-19 to address key knowledge gaps in the epidemiology of disease severity and poor clinical outcomes in India. Results from this study may help clinicians in India focus limited health resources...

Tuberculosis (TB) Aftermath

Post Date: 
2020-06-05
   |   
Countries: 
   |   
Clinical Sites: 
Drs. Vidya Mave and Jonathan Golub are co-PIs and Dr. Barthwal from DY Patil Medical College is local site PI for this study. TB Aftermath seeks to provide evidence for an effective and scalable strategy targeting HHs of treated TB cases, a high priority of the NTEP. Purpose To compare the...

Mental Health Outcomes among Health Care Professionals Involved in the Treatment and Care of COVID 19 Patients in India

Post Date: 
2020-06-01
   |   
Countries: 
   |   
Clinical Sites: 
Drs. Nikhil Gupta and Nishi Suryavanshi are leading this survey project. This study is investigating the immediate impact of the COVID-19 pandemic on mental health outcomes and overall quality of life and what are the factors associated with it among Indian Health care workers. Among health care...

Prevalence of Risk Factors for Lung Cancer and Facilitators and Barriers for Tobacco Cessation among People Living with HIV

Post Date: 
2020-04-01
   |   
Countries: 
   |   
Clinical Sites: 
India has the world’s third largest HIV epidemic, with 2.1 million people currently living with HIV and an additional 90,000 new infections each year.[29] At the same time, expansion of the HIV response under India’s premier governmental agency - the National AIDS Control Organization (NACO), has...

The Sentinel Research Network of IeDEA: A Prospective Cohort among People Living with HIV

Post Date: 
2020-03-12
   |   
Clinical Sites: 
This study is nested within the TREAT Asia HIV Observational Database initiative. The global scale up of antiretroviral therapy (ART) has significantly improved the immune recovery and life expectancy of people living with HIV (PLHIV). However, PLHIV on long-term ART now face health challenges...

Hybrid Trial for Alcohol Reduction among People with TB and HIV in India

Post Date: 
2020-02-12
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Geetanjali Chander is PI and Dr. Kakrani is local site PI at DY Patil Medical College for this study. The highest incidence of tuberculosis disease (TB) in the world is in India, accounting for 27% of all new cases globally, with approximately 86,000 among persons with HIV (PWH). Unhealthy...

Pregnancy Associated Immune Responses to Tuberculosis and HIV in India and South Africa (PARTHISA)

Post Date: 
2020-01-14
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Jyoti Mathad is Co-PI of this study. Purpose: Tuberculosis (TB) is a leading cause of maternal mortality, especially among HIV-infected women. Women are most likely to develop active TB during and immediately after pregnancy. The immunologic conditions responsible for this phenomenon are not...

Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)

Post Date: 
2019-12-30
Learn more about this effort to foster development of long-lasting therapies for illnesses that require taking medications long-term

Increasing Market and Public Health Outcomes Through Scaling Up Affordable Access Models of Short Course Preventive Therapy for TB (IMPAACT4TB)

Post Date: 
2019-12-17
   |   
Countries: 
   |   
Clinical Sites: 
Primary Objective: This study is being conducted in Brazil, Cambodia, China, Ethiopia, Ghana, Haiti, India, Indonesia, Kenya, Malawi, Mozambique, South Africa, Tanzania, and Zimbabwe. The overall goal is to reduce TB incidence among (1) people living with HIV who are on antiretroviral therapy, and...

Markers of Lung Impairment in HIV-TB Coinfected Indian Adults

Post Date: 
2019-12-11
   |   
Countries: 
   |   
Clinical Sites: 
Objectives/Aims We will compare the degree of lung impairment between HIV-TB co-infected adults (HIV-TB group) and TB cases without HIV co-infection (TB group) who successfully complete TB therapy. We hypothesize that the HIV-TB group will have a greater degree of lung...

T Cell Biomarkers and T-regulatory Responses to Pediatric TB

Post Date: 
2019-11-21
   |   
Countries: 
   |   
Clinical Sites: 
The goals of this study are to: Validate host T cell biomarkers for diagnosis of pediatric TB Investigate the phenotype and functions of T-regulatory cells in pediatric TB We will use cryopreserved PBMC samples from CTRIUMPH cohorts: Pediatric unconfirmed TB, confirmed TB, latest Tb, and no TB...

Inflammasome Genetics and Tuberculosis Treatment Outcomes

Post Date: 
2019-11-07
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is a Co-PI on this study. STUDY DESIGN We will conduct a retrospective case-cohort study nested within the CTRIUMPH and EDOTS cohorts to address our study objectives. This will enable us to measure the association of polymorphisms with multiple clinical outcomes simultaneously and...

A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of ID93 + GLA-SE Vaccine Administered to HIV-Negative Patients at 3 Time Points During Multidrug Therapy for Drug Susceptible Pulmonary TB

Post Date: 
2019-10-28
   |   
Clinical Sites: 
This study was terminated in April 2020. Vidya Mave was PI of this HIV vaccine trial. BACKGOUND: Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (Mtb). TB is one of the leading causes of morbidity and mortality around the world with an estimated 10...

Utility of Multiplexed Rapid Fever Panel Kit among Hospitalized Febrile Patients in India and Its Impact on Antimicrobial Use and Diagnosis

Post Date: 
2019-10-24
   |   
Introduction Easy to use and multiplex diagnostic tools are needed to identify common causes of fever caused by vector-borne infectious diseases. Chembio has developed dual path platform (DPP) technology which differs from traditional lateral flow rapid diagnostic tests (RDT) by...

Evaluation of a Urinary Biomarker Assay for Diagnosis and Test of Cure for Tuberculosis

Post Date: 
2019-09-09
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Jeff Tornheim is PI of this study. METHODS This study will make use of biorepository samples from the Cohort for TB Research by the Indo-US Medical Partnership (CTRIUMPh). CTRIUMPh, funded by the US NIH and Indian Department of Biotechnology, is an academic collaboration between Johns Hopkins...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date: 
2019-08-19
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date: 
2019-08-19
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB...

Pages